Guidance

Candidozyma auris (formerly Candida auris): guidance for acute healthcare settings

Candidozyma auris (C.auris): laboratory investigation, management and infection prevention and control of cases.

• From: UK Health Security Agency
• Published: 27 June 2016
• Last updated: 19 March 2025 — See all updates

Documents

Summary of recommendations

HTML

Introduction and background

HTML

Investigation in clinical laboratories

HTML

Screening of patients and contacts

HTML

Management of patients who test positive for C. auris (colonised or infected)

HTML

Infection prevention and control (IPC)

HTML

Notification, reporting and information sharing

HTML

Acknowledgements

HTML

References

HTML

Details

Candidozyma auris (C. auris) is a rapidly emerging fungal pathogen with a global distribution. Designated a critical priority fungal pathogen by the World Health Organization in 2022, C. auris can result in colonisations, severe invasive infections and outbreaks within healthcare settings. Resistance has developed to many available classes of antifungals, including the first-line antifungal agent fluconazole, with the emergence of pan-resistant strains. In non-UK settings, invasive disease has been associated with significant mortality.

This guidance outlines recommendations for the laboratory investigation, management, and infection prevention and control practices associated with C. auris in healthcare settings.

This update supersedes the previous guidance, released in 2017.

Published 27 June 2016

Last updated 19 March 2025 + show all updates

1. 19 March 2025

   Updated guidance and added summary.

2. 11 August 2017

   Updated version of guidance for laboratories, healthcare providers and healthcare professionals replaces that first published in 2016.

3. 27 June 2016

   First published.